Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC)
Kohno, H.; Nagasue, N.; Hayashi, T.; Yamanoi, A.; Uchida, M.; Ono, T.; Yukaya, H.; Kimura, N.; Nakamura, T.
Hepato-Gastroenterology 43(12): 1405-1409
1996
ISSN/ISBN: 0172-6390 PMID: 8975939 Document Number: 1325
Background/Aims: This prospective randomized study was aimed to clarify the efficacy of epirubicin after radical hepatic resection for hepatocellular carcinoma (HCC). Materials and Methods: One hundred and one patients entered the present study and were randomly allocated to Group A in which UFT (300mg/day) was given from 5th postoperative week for one year, or Group B in which a bolus injection of epirubicin (40 mg/m2) was given arterially, in addition to the same UFT administration, on day 28. Groups A and B included 40 and 48 eligible cases, respectively. Results: No obvious intergroup differences were observed including prescribed dose of UFT. The 1-, 3and 5-year survival rates (Groups A vs B) were 82 vs 90%, 50 vs 49% and 35 vs 30% (p=0.2162). Excluding 4 operative deaths, the recurrence-free survival rates were 65 vs 70%, 32 vs 37% and 14 vs 17% (p=-0.3843). Initial recurrence sites were also similar. Conclusions:A bolus arterial injection of epirubicin does not change the long term results after radical hepatic resection for HCC.
Document emailed within 1 workday
